Partial
Partially Aligned
Patient Risk:
Info
Summary
Some claims about Casodex’s active ingredient and the existence of a 50 mg oral tablet are supported by the provided label sections, but several broader generic-substitution/market and inactive-ingredient claims are not supported by the supplied label text.
Category Scores
Accurate Statements
Casodex is the brand name for bicalutamide.
Supported by 11. DESCRIPTION (CASODEX (bicalutamide) tablets)
When comparing a generic to Casodex, the generic should have the same active ingredient (bicalutamide).
Supported by 11. DESCRIPTION (CASODEX (bicalutamide))
When comparing a generic to Casodex, the generic should have the same strength.
Supported by 11. DESCRIPTION (tablets contain 50 mg of bicalutamide) and 3. DOSAGE FORMS AND STRENGTHS (50 mg tablets)
When comparing a generic to Casodex, the generic should have the same dosage form.
Supported by 3. DOSAGE FORMS AND STRENGTHS (50 mg tablets for oral administration)
Unsupported Statements
A generic Casodex would be a generic product that contains the same active ingredient (bicalutamide) in the same strength and dosing form.
Partially supported by label descriptions of active ingredient/strength/dosage form, but the label does not define 'generic' substitution requirements as stated.
The generic equivalent of Casodex is typically marketed under the active ingredient name bicalutamide.
No support for market naming practices is present in the provided label sections.
When comparing a generic to Casodex, the generic should have the same intended use/prostate cancer indication as reflected by local labeling.
The label supports Casodex’s indicated use, but does not state generic 'intended use' equivalence or reference 'local labeling' criteria.
Minor differences can exist in inactive ingredients between a generic and Casodex.
The label lists inactive ingredients of CASODEX, but does not discuss inactive-ingredient differences between generics and brand products.
Those inactive-ingredient differences usually do not change the drug’s core effect if the active ingredient and strength match.
No statement addressing effects/core performance relative to inactive-ingredient differences is present in the provided label sections.
In many markets, multiple manufacturers can sell bicalutamide as generics.
The provided label sections do not address market competition or number of generic manufacturers.
Contradictions
Important Omissions
Casodex-specific approved use requires combination therapy with an LHRH analog for Stage D2 metastatic carcinoma of the prostate; the claims do not include this required regimen/indication detail in the generic-comparison context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The provided claims are primarily about brand/generic equivalence and inactive ingredients; they do not include contraindications, boxed warnings, or dosing instructions beyond strength/dosage form. However, omission of the label’s specific indicated regimen (combination with an LHRH analog for Stage D2 metastatic prostate cancer) could lead to an inaccurate framing of indication equivalence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several generic-substitution and market/inactive-ingredient statements are not supported by the provided FDA label sections; indication equivalence is not established by the cited text.
Suggested Improvement
Limit claims to label-supported facts (CASODEX contains bicalutamide, 50 mg oral tablets) and the specific approved indication wording; avoid statements about generic marketing practices, inactive-ingredient differences, or generic intended-use equivalence unless the label text explicitly supports them.